AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass.
Adenosine 5'-monophosphate-activated protein kinase (AMPK), a regulator of energy homeostasis, has a central role in mediating the appetite-modulating and metabolic effects of many hormones and antidiabetic drugs metformin and glitazones. The objective of this study was to determine if AMPK can be activated in osteoblasts by known AMPK modulators and if AMPK activity is involved in osteoblast function in vitro and regulation of bone mass in vivo. ROS 17/2.8 rat osteoblast-like cells were cultured in the presence of AMPK activators (AICAR and metformin), AMPK inhibitor (compound C), the gastric peptide hormone ghrelin and the beta-adrenergic blocker propranolol. AMPK activity was measured in cell lysates by a functional kinase assay and AMPK protein phosphorylation was studied by Western Blotting using an antibody recognizing AMPK Thr-172 residue. We demonstrated that treatment of ROS 17/2.8 cells with AICAR and metformin stimulates Thr-172 phosphorylation of AMPK and dose-dependently increases its activity. In contrast, treatment of ROS 17/2.8 cells with compound C inhibited AMPK phosphorylation. Ghrelin and propranolol dose-dependently increased AMPK phosphorylation and activity. Cell proliferation and alkaline phosphatase activity were not affected by metformin treatment while AICAR significantly inhibited ROS 17/2.8 cell proliferation and alkaline phosphatase activity at high concentrations. To study the effect of AMPK activation on bone formation in vitro, primary osteoblasts obtained from rat calvaria were cultured for 14-17days in the presence of AICAR, metformin and compound C. Formation of 'trabecular-shaped' bone nodules was evaluated following alizarin red staining. We demonstrated that both AICAR and metformin dose-dependently increase trabecular bone nodule formation, while compound C inhibits bone formation. When primary osteoblasts were co-treated with AICAR and compound C, compound C suppressed the stimulatory effect of AICAR on bone nodule formation. AMPK is a alphabetagamma heterotrimer, where alpha is the catalytic subunit. RT-PCR analysis of AMPK subunits in ROS17/2.8 osteoblastic cells and in mouse tibia showed that the AMPKalpha1 subunit is the dominant isoform expressed in bone. We analysed the bone phenotype of 4month-old male wild type (WT) and AMPKalpha1-/- KO mice using micro-CT. Both cortical and trabecular bone compartments were smaller in the AMPK alpha1-deficient mice compared to the WT mice. Altogether, our data support a role for AMPK signalling in skeletal physiology.
Shah
M
M
Department of Veterinary Basic Sciences Royal Veterinary College, Royal College Street, London, NW1 OTU, UK.
Kola
B
B
Bataveljic
A
A
Arnett
T R
TR
Viollet
B
B
Saxon
L
L
Korbonits
M
M
Chenu
C
C
D055372:AMP-Activated Protein Kinases / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D000469:Alkaline Phosphatase / Q000378:metabolism; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001842:Bone and Bones / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology*; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D020536:Enzyme Activators / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D008687:Metformin / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D009490:Neurosecretory Systems / Q000201:enzymology; D009929:Organ Size / Q000187:drug effects; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology*; D010641:Phenotype; D021122:Protein Subunits / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D012265:Ribonucleotides / Q000494:pharmacology; D013977:Tibia / Q000187:drug effects / Q000201:enzymology
D020536:Enzyme Activators; D021122:Protein Subunits; D012333:RNA, Messenger; D012265:Ribonucleotides; D000620:Aminoimidazole Carboxamide; D008687:Metformin; D055372:AMP-Activated Protein Kinases; D000469:Alkaline Phosphatase; C031143:AICA ribonucleotide
J Biol Chem. 2007 Oct 12;282(41):30107-19
17711846
J Clin Invest. 2002 Apr;109(7):915-21
11927618
Diabet Med. 1992 Jan-Feb;9(1):30-7
1551307
Endocrinology. 2006 Jul;147(7):3196-202
16614075
Cell Signal. 2008 May;20(5):978-88
18276112
Exp Cell Res. 2006 Jun 10;312(10):1693-702
16529738
J Biol Chem. 2004 Mar 26;279(13):12005-8
14742438
Nat Med. 2005 Jul;11(7):774-9
15908955
J Biol Chem. 2005 Jul 1;280(26):25250-7
15878856
J Mol Signal. 2008 Dec 01;3:18
19046439
Annu Rev Pharmacol Toxicol. 2007;47:185-210
16879084
J Biol Chem. 2002 Jul 12;277(28):25226-32
11994296
J Endocrinol. 2005 Jan;184(1):249-56
15642801
Biochem Biophys Res Commun. 2008 Oct 24;375(3):414-9
18721796
Vitam Horm. 2008;77:239-58
17983859
J Endocrinol. 2002 Nov;175(2):405-15
12429038
J Clin Invest. 2001 Oct;108(8):1167-74
11602624
Nat Med. 2007 Oct;13(10):1234-40
17873881
Cell Metab. 2009 Nov;10(5):366-78
19883615
EMBO J. 2008 Jun 4;27(11):1537-48
18480843
Bone. 2007 Aug;41(2):206-15
17543595
J Biol Chem. 2005 Nov 25;280(47):39582-93
16176927
Physiol Rev. 2009 Jul;89(3):1025-78
19584320
Biochem Soc Trans. 2003 Feb;31(Pt 1):216-9
12546688
FASEB J. 2010 Jan;24(1):275-85
19723702
J Biol Chem. 1954 Mar;207(1):19-37
13152077
Acta Physiol (Oxf). 2009 May;196(1):115-27
19245657
Cell. 2007 Aug 10;130(3):456-69
17693256
Osteoporos Int. 2008 Jul;19(7):905-12
17924050
J Physiol. 2006 Jul 1;574(Pt 1):63-71
16613876
Cell. 2000 Jan 21;100(2):197-207
10660043
Cell Metab. 2009 Jan 7;9(1):23-34
19117544
Nature. 2005 Mar 24;434(7032):514-20
15724149
Biochem Biophys Res Commun. 2007 Mar 23;354(4):1084-8
17276402
Nature. 2004 Apr 1;428(6982):569-74
15058305
Eur J Pharmacol. 2007 Aug 13;569(1-2):155-62
17574233
Nature. 2002 Jan 17;415(6869):339-43
11797013
J Diabetes Complications. 2010 Sep-Oct;24(5):334-44
19628413
J Clin Invest. 2004 Mar;113(6):805-6
15067310
Front Biosci. 2008 Jan 01;13:3022-33
17981775
J Endocrinol Invest. 2007 Oct;30(9):RC26-30
17993761
BMC Cell Biol. 2007 Nov 29;8:51
18047638
Mol Cell Endocrinol. 2009 Oct 30;310(1-2):21-9
19376193
Acta Physiol (Oxf). 2009 May;196(1):3-14
19245650
J Cell Physiol. 2009 Dec;221(3):740-9
19725053
Front Biosci (Landmark Ed). 2009 Jan 01;14:3380-400
19273282
Am J Physiol Cell Physiol. 2000 Oct;279(4):C1220-9
11003602
J Biol Chem. 2002 Sep 6;277(36):32571-7
12065578
Am J Hypertens. 1996 Feb;9(2):188-92
8924270
J Cell Sci. 2004 Nov 1;117(Pt 23):5479-87
15509864
J Biol Chem. 2005 Jul 1;280(26):25196-201
15899896
Eur J Pharmacol. 2006 Apr 24;536(1-2):38-46
16564524
Trends Mol Med. 2008 Dec;14(12):539-49
18977694
J Appl Physiol (1985). 2001 Sep;91(3):1073-83
11509501
J Clin Endocrinol Metab. 2007 Apr;92(4):1305-10
17264176
Acta Physiol (Oxf). 2009 May;196(1):15-26
19245655
Nat Clin Pract Rheumatol. 2006 Jan;2(1):35-43
16932650
Bone. 2008 Aug;43(2):394-404
18502715
Acta Physiol (Oxf). 2009 May;196(1):175-90
19245659
Am J Physiol Endocrinol Metab. 2009 Jan;296(1):E139-46
19001547
Curr Opin Clin Nutr Metab Care. 2004 Jul;7(4):471-8
15192452
Trends Endocrinol Metab. 2006 Jul;17(5):205-15
16766204
J Biol Chem. 2004 Jan 9;279(2):1070-9
14573616
J Clin Invest. 2003 Jan;111(1):91-8
12511592
J Bone Miner Res. 2010 Feb;25(2):211-21
19594306
Am J Physiol Endocrinol Metab. 2006 Jul;291(1):E175-81
16464908
Biochem Biophys Res Commun. 2005 Dec 16;338(2):694-9
16236247
Arch Oral Biol. 2009 Oct;54(10):951-62
19700143
Mol Cell. 2005 Apr 29;18(3):283-93
15866171
J Physiol. 2006 Jul 1;574(Pt 1):7-15
16644800
Endocrinology. 2007 Jun;148(6):2669-80
17332064
Diabetes. 2010 Mar;59(3):554-63
19934007